The FDA accepted vepdegestrant’s new drug application for ER+/HER2–, ESR1-mutated advanced breast cancer with a June 5, 2026, ...

Q2 2025 Management View Ian C. Mortimer, President and CEO, highlighted that Xenon has completed patient recruitment in its pivotal X-TOLE2 Phase III clinical trial for azetukalner in focal onset ...

Q2 2025 Management View CEO Yu-Hsin Lin reported "excellent progress in the quarter towards advancing Tinlarebant narrowband in patients living with Stargardt's disease and geographic atrophy," ...

The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling ...

US kefir maker Lifeway Foods turned down two offers from the French giant – one of its shareholders – last year.

An NDA is designed to prevent information from becoming public. There are different types of non-disclosure agreements. A mutual NDA is one in which two or more parties are sharing confidential ...

But when Perkins decided to break her NDA in the Financial Times in the fall of 2017, she found that no law firm would represent her. “No one would touch me,” she said. “It was infuriating.” ...